Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes.
Anti-Tat vaccination experiments were carried out in mice with a view to inducing systemic in addition to mucosal immunity. For this, three types of immunizing preparations were tested, which consisted of Tat toxoid embedded in either an adjuvant oily structure (IMS), or nanoparticles of chitosan, or microparticles of polylactide-co-glycolide (PLG). Administered by either the intranasal or oral route all preparations triggered anti-Tat IgG and IgA antibodies. Sera from mice immunized with either of these preparations could also inhibit significantly the Tat transactivating activity. These results open up a new avenue to the development of an effective anti-AIDS protective vaccine.
Le Buanec
H
H
Laboratoire de Physiologie Cellulaire, Université Pierre et Marie Curie, Paris, France.
Vetu
C
C
Lachgar
A
A
Benoit
M A
MA
Gillard
J
J
Paturance
S
S
Aucouturier
J
J
Gane
V
V
Zagury
D
D
Bizzini
B
B
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D015696:Gene Products, tat / Q000097:blood / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D014121:Toxoids / Q000008:administration & dosage* / Q000276:immunology*; D014611:Vaccination; D054322:tat Gene Products, Human Immunodeficiency Virus
D015696:Gene Products, tat; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D014121:Toxoids; D054322:tat Gene Products, Human Immunodeficiency Virus